Geron (NASDAQ:GERN) Lifted to Sell at StockNews.com

StockNews.com upgraded shares of Geron (NASDAQ:GERN) to a sell rating in a research note published on Monday morning.

Other equities research analysts also recently issued research reports about the stock. Robert W. Baird downgraded shares of Geron from an outperform rating to a neutral rating and set a $4.50 price objective for the company. in a report on Tuesday, April 30th. Stifel Nicolaus raised their price target on shares of Geron from $6.00 to $7.00 and gave the stock a buy rating in a research report on Monday, June 10th. TD Cowen assumed coverage on shares of Geron in a report on Monday, April 29th. They issued a buy rating and a $10.00 target price on the stock. Wedbush restated an outperform rating and issued a $7.00 price objective on shares of Geron in a research report on Friday, June 7th. Finally, Barclays assumed coverage on shares of Geron in a report on Monday, June 10th. They issued an overweight rating and a $9.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus price target of $6.93.

Geron Stock Up 2.0 %

Shares of GERN stock traded up $0.09 during trading hours on Monday, reaching $4.60. The company had a trading volume of 7,718,620 shares, compared to its average volume of 11,380,957. The company has a market capitalization of $2.73 billion, a P/E ratio of -13.06 and a beta of 0.48. Geron has a twelve month low of $1.64 and a twelve month high of $5.34. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.67 and a current ratio of 3.67. The stock’s fifty day simple moving average is $4.47 and its 200 day simple moving average is $3.45.

Insider Buying and Selling

In other Geron news, EVP Faye Feller sold 287,900 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $4.63, for a total transaction of $1,332,977.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, COO Andrew J. Grethlein sold 674,348 shares of Geron stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $4.56, for a total value of $3,075,026.88. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Faye Feller sold 287,900 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $4.63, for a total value of $1,332,977.00. The disclosure for this sale can be found here. Insiders have sold 1,562,248 shares of company stock worth $6,808,004 in the last 90 days. Insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Geron

A number of institutional investors have recently added to or reduced their stakes in GERN. National Bank of Canada FI grew its position in shares of Geron by 1,200.0% in the 2nd quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 6,000 shares during the last quarter. Crewe Advisors LLC boosted its position in shares of Geron by 870.0% during the first quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 8,700 shares during the last quarter. Kingsview Wealth Management LLC bought a new stake in shares of Geron in the first quarter worth approximately $34,000. American Trust purchased a new stake in Geron during the 1st quarter valued at $38,000. Finally, CIBC Asset Management Inc increased its position in Geron by 32.7% during the second quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 3,805 shares during the last quarter. 73.71% of the stock is currently owned by institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.